As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Public debut for ENT company signals continued strength among new listings in a season of volatility

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and throat diseases company priced late Thursday in the final hours of a month in

Read the full 490 word article

How to gain access

Continue reading with a
two-week free trial.